Endocrine Abstracts

Background: Pancreatic neuroendocrine tumors (P-NETs) are a rare cancer with increasing incidences worldwide. Low-grade P-NETs are unique in that they express high levels of Somatostatin Receptor Type 2 (SSTR2), which represents a target for both tumor imaging and therapeutics. P-NET grade inversely correlates with SSTR2 tumor staining, and higher tumor grade is associated with poor patient prognosis. Unfortunately, application of SSTR2-targeted treatment options is currently ...